Singleplex Immunoassay Market Size to Reach USD 5.92 Billion by 2030 | Growth Trends & Insights
Global singleplex immunoassay
market is undergoing robust expansion as precision diagnostics,
biomarker-driven research, and personalized medicine gain traction across
healthcare and life sciences. Valued at USD 3.52 billion in 2022, the
market is projected to grow from USD 3.79 billion in 2024 to USD 5.92
billion by 2030, registering a strong CAGR of 7.7% during the
forecast period. This growth highlights the continued reliance on
high-specificity, single-analyte testing for clinical diagnostics,
pharmaceutical research, and translational medicine worldwide.
Access the market report https://www.24lifesciences.com/singleplex-immunoassay-market-9037
Emerging
Healthcare Trends Driving Market Evolution
In 2025, the singleplex immunoassay
market is being shaped by the convergence of precision diagnostics,
automation, and biomarker-centric healthcare. Despite the rise of multiplex
platforms, singleplex assays remain indispensable where definitive, quantitative
measurement of individual biomarkers is required. Advances in AI-enabled
laboratory workflows, automated immunoassay analyzers, and digital data
management systems are improving throughput while maintaining analytical
accuracy.
The growing emphasis on personalized
medicine and companion diagnostics further reinforces demand for validated
single-target assays, particularly in oncology, infectious diseases, and
autoimmune disorders. Regulatory initiatives aimed at improving diagnostic
quality and laboratory standardization are also supporting market confidence,
aligning with global diagnostic quality priorities promoted by the World
Health Organization
Key
Market Drivers Supporting Expansion
Several fundamental drivers continue
to propel the singleplex immunoassay market forward:
- Rising prevalence of chronic and infectious diseases, increasing diagnostic testing volumes
- High demand for precise biomarker quantification in clinical trials and patient monitoring
- Technological integration in laboratories, including automation and AI-assisted
analysis
- Strong investment in pharmaceutical and biotechnology
R&D
- Regulatory focus on accuracy and standardization in in-vitro diagnostics
Collectively, these drivers
reinforce the critical role of singleplex immunoassays in generating reliable,
clinically actionable data.
Download
insights https://www.24lifesciences.com/download-sample/9037/singleplex-immunoassay-market
Competitive
Landscape: Leading Companies
The market features a competitive
landscape dominated by global life sciences and diagnostics leaders that
continuously invest in assay innovation, antibody development, and integrated
platforms. Key companies shaping the singleplex immunoassay market include:
- Thermo Fisher Scientific Inc. – expanding immunoassay portfolios and automated
laboratory solutions
- Merck KGaA
– advancing high-quality reagents and assay development technologies
- Bio-Rad Laboratories, Inc. – strengthening ELISA-based and chemiluminescent assay
platforms
- QIAGEN N.V.
– integrating molecular and immunoassay workflows for translational
research
- Danaher Corporation (including Cytiva and Beckman
Coulter) – driving innovation in
diagnostics instrumentation and reagents
These organizations focus on
strategic collaborations, product launches, and R&D investments to address
evolving laboratory and clinical needs.
Segment
Insights & Regional Overview
By type, protein-based
assays dominate the market, led by ELISA technologies widely used for
protein quantification in diagnostics and research. Their proven reliability,
sensitivity, and standardized protocols ensure sustained adoption.
By application, pharmaceutical
and biotechnology companies represent the leading segment, leveraging
singleplex immunoassays for drug discovery, pharmacokinetics, biomarker
validation, and clinical trial monitoring.
By end user, clinical
diagnostics holds the largest share, driven by routine disease testing,
screening programs, and therapeutic monitoring that require robust
single-analyte assays.
From a detection technology
perspective, chemiluminescence leads due to its high sensitivity, broad
dynamic range, and compatibility with automated systems.
By sample type, blood and serum samples dominate, reflecting
their central role in diagnostic and monitoring workflows.
Regionally, North America
maintains market leadership, supported by advanced research infrastructure,
high healthcare spending, and early adoption of precision diagnostics.
Europe follows closely, characterized by strong regulatory standards and
a mature in-vitro diagnostics ecosystem.
The Asia-Pacific region is the fastest-growing market, driven by
expanding healthcare infrastructure, rising diagnostics demand, and increasing
biopharmaceutical R&D.
South America and the Middle East & Africa represent
developing markets, with growth linked to improving laboratory capacity and
public health investments.
Explore
analysis https://www.24lifesciences.com/singleplex-immunoassay-market-9037
Technological
Advancements & Strategic Outlook
Can
Precision Diagnostics and Automation Redefine the Future of Singleplex Testing?
The future of the singleplex
immunoassay market lies in automation, assay miniaturization, and digital
integration. Enhanced chemiluminescent platforms, AI-driven quality
control, and workflow optimization are enabling laboratories to scale testing
while preserving analytical rigor. As healthcare systems increasingly rely on
biomarker-driven decision-making, singleplex assays will remain essential for
confirmatory testing and high-confidence diagnostics.
Key
Benefits of the 24LifeSciences Report
The Singleplex Immunoassay Market
Report from 24LifeSciences delivers:
- In-depth segmentation by type, application, end user,
detection technology, and sample type
- Market sizing, CAGR analysis, and forecasts through
2030
- Competitive landscape assessment and strategic
benchmarking
- Insights into investment opportunities across
diagnostics and life sciences
Stay
ahead https://www.24lifesciences.com/singleplex-immunoassay-market-9037
Future
Perspective
As life sciences and healthcare
continue their shift toward precision diagnostics and data-driven medicine,
the singleplex immunoassay market offers sustained growth opportunities
for assay developers, diagnostics providers, and investors. Stakeholders who
align innovation with accuracy, regulatory compliance, and evolving clinical
needs will remain at the forefront of this expanding global market.
About 24lifesciences
Founded in 2017, 24LifeScience has emerged as a trusted research and
analytics partner for organizations operating within the global life sciences
and chemical industries. Our core mission is to provide intelligent,
future-ready insights that help clients stay ahead in an increasingly complex
and innovation-driven market
International: +1(332)
2424 294 | Asia: +91 9425150513 (Asia)
Website: http://www.24lifesciences.com
Follow us on LinkedIn: http://www.linkedin.com/company/lifesciences24
Comments
Post a Comment